- GSK
- 29 April 2024 17:21:19
Source: Sharecast
GSK's DREAMM-7 head-to-head phase III trial of its second-line treatment for relapsed or refractory multiple myeloma met its primary endpoint of progression-free survival and showed that belantamab mafodotin, when combined with bortezomib plus dexamethasone, had "significantly extended" the time to disease progression or death.
The London-listed group said a "strong and clinically meaningful" overall survival trend with nominal probabiliity value of less than 0.0005 was also observed, with the trial continuing in order to follow up for overall survival data.
GSK's Hesham Abdullah said: "Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action.
"We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard of care regimen."
As of 0855 GMT, GSK shares were up 0.15% at 1,424.80p.
Reporting by Iain Gilbert at Sharecast.com